Small renal mass(SRM)incidence has been increasing over last decades due to the widespread access to diagnostic tools and is now accounting for 48%e66%of all renal cell carcinoma(RCC)diagnoses[1].The optimal managemen...Small renal mass(SRM)incidence has been increasing over last decades due to the widespread access to diagnostic tools and is now accounting for 48%e66%of all renal cell carcinoma(RCC)diagnoses[1].The optimal management of SRM is still debated since approximately 25%of T1a is benign lesions.The role of active surveillance(AS)and the problem of SRM overtreatment are widely described in the current literature.However,RCC mortality has remained stable over the last 2 decades.The major strength of AS is the“tetrafecta”concept as it brings renal function preservation,safe oncological outcomes,and no surgical complications,and it maintains quality of life.AS is nowadays considered as a safe strategy for many SRMs.展开更多
文摘Small renal mass(SRM)incidence has been increasing over last decades due to the widespread access to diagnostic tools and is now accounting for 48%e66%of all renal cell carcinoma(RCC)diagnoses[1].The optimal management of SRM is still debated since approximately 25%of T1a is benign lesions.The role of active surveillance(AS)and the problem of SRM overtreatment are widely described in the current literature.However,RCC mortality has remained stable over the last 2 decades.The major strength of AS is the“tetrafecta”concept as it brings renal function preservation,safe oncological outcomes,and no surgical complications,and it maintains quality of life.AS is nowadays considered as a safe strategy for many SRMs.
